17Feb 2020

COMPARISON OF TWO COMMONLY USED SEQUENTIAL THERAPY REGIMENS FOR ERADICATION OF HELICOBACTER PYLORI INFECTION

  • Department of Gastroenterology and Hepatology, Government Medical College Srinagar Kashmir India.
  • Department of Bio-Statistics, Preventive and Social Medicine, Government Medical College Srinagar Kashmir India.
Crossref Cited-by Linking logo
  • Abstract
  • References
  • Cite This Article as
  • Corresponding Author

Aim: To compare the efficacy of levofloxacin based and clarithromycin based sequential therapies for eradication of Helicobacter pylori infection. Methods: From january 2017 to december 2018, 260 patients with H. pylori infection randomly received 14 d of levofloxacin-based sequential therapy (LEVO-ST group, n = 130) or clarithromycin-based sequential therapy (CLA-ST group, n = 130).H.pylori infection was defined on the basis of either histologic evidence of H. pylori by modified Giemsa staining: or a positive rapid urease test by gastric mucosal biopsy. Successful eradication therapy for H.pylori infection was defined as a negative 13-Carbon ?urea breath test four weeks after the end of eradication treatment.Compliance was defined as good when drug intake was at least 90%. H. Pylori eradication rates, patient compliance with drug treatment, adverse events, and factors influencing the efficacy of eradicationtherapy were evaluated. Results: The eradication rates by intention-to-treatanalysis were 89% (116/130: 95%ci: 86.2%-95.4%)in the levo-st group and 86% (112/130: 95%ci:65.8%-77.4%) in the cla-st group (p = 0.450). Theeradication rates by per-protocol analysis were 91%(114/124) 95%ci: 89.1%-98.1%) in the LEVO-ST groupand 87% (106/122: 95%ci: 69.4%-81.8%) in the CLA-ST group (p = 0.227). Compliance was 100% in bothgroups. The adverse event rates were 17.6 % (22/125) and 28.6% (35/122) in the LEVO-ST and CLA-ST group,respectively (p = 0.038). Most of the adverse eventswere mild-to-moderate in intensity: there was none serious enough to cause discontinuation of treatmentin either group. Conclusion: The 14-d levofloxacin-based sequential therapy has high efficacy for H. pylori eradication effective. Moreover, it showed excellent patient compliance and safety compared to the 14-d clarithromycin-based sequential therapy.

  1. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983:1:1273
  2. Moss SF, Malfertheiner P. Helicobacter and gastric malignancies. Helicobacter. 2007:12Suppl 1:23?30.
  3. Yamada T, Searle JG, Ahnen D, Aipers DH, Greenberg HB, Gray M, et al. Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994:272:65?69.
  4. International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC MonogrEvalCarcinog Risks Hum 1994:61:177?240.
  5. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with helicobacter pylori-associated gastric or duodenal ulcer. Aliment PharmacolTher. 2001:15:1949?58.
  6. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993:342:575?7.
  7. Bae SE, Jung HY, Kang J, Park YS, Baek S, Jung JH, Choi JY, Kim MY, Ahn JY, Choi KS, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014:109:60?7
  8. Lee SW, Kim HJ, Kim JG. Treatment of helicobacter pylori infection in Korea: a systematic review and meta-analysis. J Korean Med Sci. 2015:30:1001?9.
  9. Lam SK, Talley NJ. Report of the 1997 Asia pacific consensus conference on the management of helicobacter pylori infection. J Gastroenterol Hepatol.1998:13:1?12.
  10. Kim N, Kim JJ, Choe YH, Kim HS, Kim JI, Chung IS. Korean college of helicobacter and upper gastrointestinal research: korean association of gastroenterology. Diagnosis and treatment guidelines for helicobacter pylori infection in Korea.Korean J Gastroenterol.2009 : 54:269?78.
  11. Tong JL, Ran ZH, Shen J, Xiao SD. Sequantial therapy vs. standardtriple therapies for Helicobacter pylori infection: meta-analysis. JClin Pharm Ther 2009:34:41-53.
  12. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013:62(1):34?42.
  13. Onder G, Aydin A, Akarca U, Tekin F, Ozutemiz O, Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J ClinGastroenterol 2007:41(8):747?50.
  14. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010:59:1143?53.
  15. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment PharmacolTher 2003:17:1333?43.
  16. 16 Tepes B, O?Connor A, Gisbert JP, et al. Treatment of Helicobacter pylori infection 2012. Helicobacter 2012:17(Suppl 1):36?42.
  17. Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi F, MehrabaniM,Hosseinzadeh H, et al. In vitro antibacterial activity of some Iranianmedicinal plant extracts against Helicobacter pylori. Nat Prod Res 2011:25:1059?1066.
  18. Franceschi F, Gasbarrini A. Helicobacter pylori and extragastricdiseases.BestPract Res ClinGastroenterol 2007: 21:325?334.
  19. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, et al.Review article: the global emergence of Helicobacter pylori antibioticresistance. Aliment PharmacolTher 2016: 43:514?533.
  20. Diab M, El-Dine S, Aboul-Fadl L, Shemis M, Omran Z. Helicobacter pyloricag pathogenicity Island genes among dyspeptic patients with chronic gastritis. Egypt J Med Microbial 2009: 18:43?53.
  21. Waleed A. Ismail, Ehab F. Mostafa .A comparison between conventional triple therapy andsequential therapy on tolerance of treatment and eradication of Helicobacter pylori infection in Egyptian patients. The Egyptian Journal of Internal Medicine 2018, 30:90?95
  22. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al.Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015: 64:1353?1367.
  23. De Francesco V, Zullo A, Margiotta M, Marangi S, Burattini O, Berloco P, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment PharmacolTher 2004:19:407-14.
  24. Oh HS, Lee DH, Seo JY, Cho YR, Kim N, Jeoung SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Cho HJ, Jung HC, Song IS. Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study. J GastroenterolHepatol2012: 27: 504-509
  25. Lim JH, Lee DH, Choi C, Lee ST, Kim N, Jeong SH, Kim JW,Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jang ES, Song Is,Jung HC. Clinical outcomes of two-week sequential and concomitanttherapies for Helicobacter pylori eradication: a randomized pilotstudy. Helicobacter 2013: 18: 180-186
  26. Polat Z, Kadayifci A, Kantarcioglu M, Ozcan A, Emer O, UygunA.Comparison of levofloxacin-containing sequential and standard tripletherapies for the eradication of Helicobacter pylori.Eur J Intern Med2012: 23:165?168.
  27. Qian J, Ye F, Zhang J, Yang YM, Tu HM, Jiang Q, et al. Levofloxacin containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012: 17:478?485.
  28. Zullo A, de Francesco V, Hassan C, Ridola L, Repici A, Bruzzese V, etal.Modified sequential therapy regimens for Helicobacter pylori eradication: asystematic review. Dig Liver Dis 2013: 45:18?22
  29. Romano M, Cuomo A, Gravina AG, Miranda A, Iovene MR, Tiso A, et al.Empirical levofloxacin-containing versus clarithromycin-containing sequentialtherapy for Helicobacter pylori eradication: a randomised trial. Gut 2010:59:1465?1470.
  30. 29 Jyh-Ming Liou, Chieh-Chang Chen et al , Sequential versus triple therapy for the fi rst-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013: 381: 205?13.
  31. Kim SE, Park MI, Park SJ, Moon W, Choi YJ, Cheon JH, Kwon HJ, Ku KH,Yoo CH, Kim JH, et al. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy. KoreanJ Intern Med. 2015:30:801?7.
  32. Moayyedi P, Chalmers DM, Axon AT. Patient factors that predict failure ofomeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori.JGastroenterol. 1997:32:24?7.
  33. Suzuki T, Matsuo K, Ito H, Sawaki A, Hirose K, Wakai K, Sato S, Nakamura T, Yamao K, Ueda R, et al. Smoking increases the treatment failure forHelicobacter pylori eradication. Am J Med. 2006:119:217?24.
  34. M?graud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004: 53: 1374-1384
  35. Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J ClinGastroenterol2006: 40: 683-687.

[Shabir Shiekh, Zafar Wani, Shafat Lone and Feroz Wani (2020); COMPARISON OF TWO COMMONLY USED SEQUENTIAL THERAPY REGIMENS FOR ERADICATION OF HELICOBACTER PYLORI INFECTION Int. J. of Adv. Res. 8 (Feb). 61-66] (ISSN 2320-5407). www.journalijar.com

Shabir Shiekh
Department of Gastroenterology and Hepatology, Government Medical College Srinagar Kashmir India.

DOI:

Article DOI: 10.21474/IJAR01/10435      
DOI URL: http://dx.doi.org/10.21474/IJAR01/10435

Download Full Paper

Download PDF No. of Downloads: 17 | No. of Views: 39